| 1 | Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China | JAMA Neurology | 2020 | 4,469 |
| 2 | Amyloid-β and Tau | JAMA Neurology | 2014 | 1,685 |
| 3 | Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs | JAMA Neurology | 2018 | 1,131 |
| 4 | Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease | JAMA Neurology | 2017 | 787 |
| 5 | Worldwide Incidence of Aneurysmal Subarachnoid Hemorrhage According to Region, Time Period, Blood Pressure, and Smoking Prevalence in the Population | JAMA Neurology | 2019 | 684 |
| 6 | Inflammation and Neuroprotection in Traumatic Brain Injury | JAMA Neurology | 2015 | 664 |
| 7 | Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease | JAMA Neurology | 2019 | 653 |
| 8 | Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019 | JAMA Neurology | 2020 | 633 |
| 9 | The Preclinical Alzheimer Cognitive Composite | JAMA Neurology | 2014 | 622 |
| 10 | Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology | JAMA Neurology | 2024 | 597 |
| 11 | Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology | JAMA Neurology | 2019 | 592 |
| 12 | Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease | JAMA Neurology | 2013 | 563 |
| 13 | Sleep Quality and Preclinical Alzheimer Disease | JAMA Neurology | 2013 | 549 |
| 14 | Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury | JAMA Neurology | 2019 | 549 |
| 15 | Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease | JAMA Neurology | 2019 | 544 |
| 16 | Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders | JAMA Neurology | 2018 | 527 |
| 17 | Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials | JAMA Neurology | 2020 | 515 |
| 18 | Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease | JAMA Neurology | 2017 | 491 |
| 19 | New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression | JAMA Neurology | 2015 | 489 |
| 20 | Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies | JAMA Neurology | 2014 | 484 |
| 21 | Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains | JAMA Neurology | 2017 | 479 |
| 22 | Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort | JAMA Neurology | 2017 | 471 |
| 23 | Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum | JAMA Neurology | 2021 | 471 |
| 24 | Burden of Neurological Disorders Across the US From 1990-2017 | JAMA Neurology | 2021 | 465 |
| 25 | Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza | JAMA Neurology | 2020 | 460 |
| 26 | Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease | JAMA Neurology | 2022 | 441 |
| 27 | Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy | JAMA Neurology | 2016 | 439 |
| 28 | Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease | JAMA Neurology | 2016 | 436 |
| 29 | Evaluation of Galcanezumab for the Prevention of Episodic Migraine | JAMA Neurology | 2018 | 431 |
| 30 | Association of Delirium With Long-term Cognitive Decline | JAMA Neurology | 2020 | 431 |
| 31 | Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo | JAMA Neurology | 2019 | 423 |
| 32 | Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies | JAMA Neurology | 2020 | 411 |
| 33 | Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury | JAMA Neurology | 2016 | 406 |
| 34 | Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US | JAMA Neurology | 2022 | 399 |
| 35 | Global Prevalence and Incidence of Tinnitus | JAMA Neurology | 2022 | 398 |
| 36 | Association of Proton Pump Inhibitors With Risk of Dementia | JAMA Neurology | 2016 | 392 |
| 37 | Association of Sleep-Disordered Breathing With Cognitive Function and Risk of Cognitive Impairment | JAMA Neurology | 2017 | 374 |
| 38 | Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression | JAMA Neurology | 2014 | 372 |
| 39 | Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression | JAMA Neurology | 2016 | 370 |
| 40 | Self-reported Sleep and β-Amyloid Deposition in Community-Dwelling Older Adults | JAMA Neurology | 2013 | 369 |
| 41 | Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease | JAMA Neurology | 2021 | 369 |
| 42 | Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid | JAMA Neurology | 2017 | 368 |
| 43 | Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease | JAMA Neurology | 2018 | 367 |
| 44 | The Idiopathic Intracranial Hypertension Treatment Trial | JAMA Neurology | 2014 | 365 |
| 45 | Parkinson Disease Subtypes | JAMA Neurology | 2014 | 362 |
| 46 | Midlife Hypertension and 20-Year Cognitive Change | JAMA Neurology | 2014 | 354 |
| 47 | Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease | JAMA Neurology | 2018 | 345 |
| 48 | Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease | JAMA Neurology | 2018 | 344 |
| 49 | Dementia Risk After Traumatic Brain Injury vs Nonbrain Trauma | JAMA Neurology | 2014 | 341 |
| 50 | Recovery After Mild Traumatic Brain Injury in Patients Presenting to US Level I Trauma Centers | JAMA Neurology | 2019 | 341 |